Patients involved in early tests of a Russian coronavirus vaccine developed antibodies with "no serious adverse events", according to research published in The Lancet Friday, but experts said the trials were too small to prove safety and effectiveness.

COVID-19: Russia vaccine 'passes early trial test'

The U.S. Centers for Disease Control and Prevention (CDC) has asked state public health officials to prepare to distribute a potential coronavirus vaccine to high-risk groups as soon as late October, documents published by the agency showed on Wednesday.

US CDC tells states to prep for COVID-19 vaccine distribution

US: States to brace for vaccine distribution by November 1

In the race to find a cure for the coronavirus infection, Texas-based Baylor College of Medicine (BCM) has entered into a licensing agreement with Indian pharmaceutical company Biological E Limited (BE) for the development of a safe, effective and affordable vaccine.

According to BCM, Hyderabad-headquartered BE has licenced the recombinant protein COVID-19 vaccine candidate developed at Baylor.

The company engaged in licence negotiations with the BCM Ventures team after initial discussions on Baylor's technology and how it could possibly inform a vaccine to address the current global pandemic.

The company will leverage its past experience for the further development and commercialisation of the vaccine candidate, which is currently produced using a proven yeast-based expression technology, the Texas-based BCM said.

"Recent information that India has become the third-leading nation in terms of COVID-19 cases has sparked concern that COVID-19 will become widespread and a serious and deadly infection across the crowded urban areas of South Asia," said Dr Peter Hotez, professor and dean of the National School of Tropical Medicine at Baylor, at a webinar organised by the Consul General of India in Houston, Aseem Mahajan, last week.

India has recorded 33, 87,500 coronavirus cases and 61,529 fatalities due to the disease, while the US is leading the chart with over 5,869,000 cases and 180,800 deaths.

"The healthcare sector is predicted to grow steadily in India and the US. Given the complementarities, companies in both the countries have a great opportunity to build synergies including to partner together for global supply chains, joint research and manufacturing," Mahajan told PTI.

Hotez and his colleagues have already been making SARs and MERS vaccines. "Then, when we got word about COVID-19, we saw that the sequence for the new virus was similar to some of the viruses that we were already making vaccines for," said Hotez, who is also the co-director of Texas Children's Centre for Vaccine Development.

Hotez and his team were able to quickly move on to creating a COVID-19 vaccine, which resulted in the collaboration with a large vaccine producer in India.

"They have the capacity to make a billion doses of the vaccine that we've developed at Baylor College of Medicine."

"We're very worried that a lot of the low and middle income countries will be kind of pushed aside if we only rely on the Operation Warp Speed vaccines so we think what we do at Texas Children's and Baylor should fill that critically important gap," he said.

The vaccine is still in trials in India with the hope that it will be able to roll out sometime next year.

"For the past two decades, our vaccine centre has been advancing global health vaccines to prevent neglected and emerging diseases," said associate dean Dr Maria Elena Bottazzi.

"We are therefore well suited to embark on this important collaboration with BE and look forward to facilitating the technology transfer for the COVID-19 vaccine to India and for the world. The current focus is on transfer of the technology for BE to initiate scale-up of the manufacturing process and undertake further development of the vaccine candidate," she said.

Meanwhile, the BE in a statement said the partnership with Baylor would help accelerate the development of an affordable vaccine, especially for India and other low- and middle-income nations.

"If the vaccine development is successful, we expect to make several hundred million doses of the vaccine available annually," said Narnder Dev Mantena, director of BioE Holdings Inc, who heads BE's novel vaccine initiative.

In the race to find a cure for the coronavirus infection, Texas-based Baylor College of Medicine (BCM) has entered into a licensing agreement with Indian pharmaceutical company Biological E Limited (BE) for the development of a safe, effective and affordable vaccine.

In the race to find a cure for the coronavirus infection, Texas-based Baylor College of Medicine (BCM) has entered into a licensing agreement with Indian pharmaceutical company Biological E Limited (BE) for the development of a safe, effective and affordable vaccine. According to BCM, Hyderabad-headquartered BE has licenced the recombinant protein COVID-19 vaccine candidate developed at Baylor. The company engaged in licence negotiations with the BCM Ventures team after initial discussions on Baylor's technology and how it could possibly inform a vaccine to address the current global pandemic. The company will leverage its past experience for the further development and commercialisation of the vaccine candidate, which is currently produced using a proven yeast-based expression technology, the Texas-based BCM said. "Recent information that India has become the third-leading nation in terms of COVID-19 cases has sparked concern that COVID-19 will become widespread and a serious and deadly infection across the crowded urban areas of South Asia," said Dr Peter Hotez, professor and dean of the National School of Tropical Medicine at Baylor, at a webinar organised by the Consul General of India in Houston, Aseem Mahajan, last week. India has recorded 33, 87,500 coronavirus cases and 61,529 fatalities due to the disease, while the US is leading the chart with over 5,869,000 cases and 180,800 deaths. "The healthcare sector is predicted to grow steadily in India and the US. Given the complementarities, companies in both the countries have a great opportunity to build synergies including to partner together for global supply chains, joint research and manufacturing," Mahajan told PTI. Hotez and his colleagues have already been making SARs and MERS vaccines. "Then, when we got word about COVID-19, we saw that the sequence for the new virus was similar to some of the viruses that we were already making vaccines for," said Hotez, who is also the co-director of Texas Children's Centre for Vaccine Development. Hotez and his team were able to quickly move on to creating a COVID-19 vaccine, which resulted in the collaboration with a large vaccine producer in India. "They have the capacity to make a billion doses of the vaccine that we've developed at Baylor College of Medicine." "We're very worried that a lot of the low and middle income countries will be kind of pushed aside if we only rely on the Operation Warp Speed vaccines so we think what we do at Texas Children's and Baylor should fill that critically important gap," he said. The vaccine is still in trials in India with the hope that it will be able to roll out sometime next year. "For the past two decades, our vaccine centre has been advancing global health vaccines to prevent neglected and emerging diseases," said associate dean Dr Maria Elena Bottazzi. "We are therefore well suited to embark on this important collaboration with BE and look forward to facilitating the technology transfer for the COVID-19 vaccine to India and for the world. The current focus is on transfer of the technology for BE to initiate scale-up of the manufacturing process and undertake further development of the vaccine candidate," she said. Meanwhile, the BE in a statement said the partnership with Baylor would help accelerate the development of an affordable vaccine, especially for India and other low- and middle-income nations. "If the vaccine development is successful, we expect to make several hundred million doses of the vaccine available annually," said Narnder Dev Mantena, director of BioE Holdings Inc, who heads BE's novel vaccine initiative.

US college ties up with Indian firm for Covid vaccine production 

The World Health Organization recently said that countries need to discard their own interests when dealing with the ongoing coronavirus pandemic, or it could continue to get worse.

"(Acting) strategically and globally is actually in each country's national interest - no one is safe until everyone is safe," Tedros Adhanom Ghebreyesus said on Tuesday. During a virtual briefing, he also while called for an end to "vaccine nationalism".

He also called for countries to ensure a global supply of potential vaccines, otherwise the pandemic could continue to escalate.

Vaccine efforts on

Additionally, the WHO chief has sent out a letter to all WHO members asking them to join the multilateral COVAX vaccine effort.

As of now, over 21.9 million in the world have been infected by COVID-19, with 772,647 deaths recorded worldwide.

Also read:&nbsp;<a href="https://www.wionews.com/world/who-says-people-in-20s-30s-40s-increasingly-driving-coronavirus-pandemic-321437" hreflang="en">WHO says people in 20s, 30s, 40s increasingly driving coronavirus pandemic</a>

Earlier today, the World Health Organization said that it was worried that the spread of COVID-19 now may be driven by people in their 20s, 30s, and 40s.

The organisation added that most patients in the age brackets did not show symptoms, which could in turn continue to infect at-risk groups.

Younger people now the primary carriers

The organisation claimed that the number of younger people contracting the virus had risen across the world, which might in turn cause fatalities among vulnerable groups.

The elderly and people with co-morbidities, especially in poor countries with inadequate healthcare and densely populated areas, could face the virus’ wrath.

Also read:&nbsp;<a href="/world/who-says-no-evidence-of-coronavirus-on-frozen-food-packets-320368" hreflang="en">WHO says no evidence of coronavirus on frozen food packets</a>

"The epidemic is changing," WHO’s Western Pacific regional director, Takeshi Kasai, said during a virtual briefing.

"People in their 20s, 30s and 40s are increasingly driving the spread. Many are unaware they are infected."

"This increases the risk of spillovers to the more vulnerable," he added.

The World Health Organization recently said that countries need to discard their own interests when dealing with the ongoing coronavirus pandemic, or it could continue to get worse.

The World Health Organization recently said that countries need to discard their own interests when dealing with the ongoing coronavirus pandemic, or it could continue to get worse. "(Acting) strategically and globally is actually in each country's national interest - no one is safe until everyone is safe," Tedros Adhanom Ghebreyesus said on Tuesday. During a virtual briefing, he also while called for an end to "vaccine nationalism". He also called for countries to ensure a global supply of potential vaccines, otherwise the pandemic could continue to escalate. Vaccine efforts on Additionally, the WHO chief has sent out a letter to all WHO members asking them to join the multilateral COVAX vaccine effort. As of now, over 21.9 million in the world have been infected by COVID-19, with 772,647 deaths recorded worldwide. Also read: WHO says people in 20s, 30s, 40s increasingly driving coronavirus pandemic Earlier today, the World Health Organization said that it was worried that the spread of COVID-19 now may be driven by people in their 20s, 30s, and 40s. The organisation added that most patients in the age brackets did not show symptoms, which could in turn continue to infect at-risk groups. Younger people now the primary carriers The organisation claimed that the number of younger people contracting the virus had risen across the world, which might in turn cause fatalities among vulnerable groups. The elderly and people with co-morbidities, especially in poor countries with inadequate healthcare and densely populated areas, could face the virus’ wrath. Also read: WHO says no evidence of coronavirus on frozen food packets "The epidemic is changing," WHO’s Western Pacific regional director, Takeshi Kasai, said during a virtual briefing. "People in their 20s, 30s and 40s are increasingly driving the spread. Many are unaware they are infected." "This increases the risk of spillovers to the more vulnerable," he added.

'Vaccine nationalism' must end to ensure global inoculation: WHO

There are several contenders global as well as domestic in the race to develop the COVID-19 vaccine. Watch report.

Who all are the major COVID-19 vaccine global and domestic contenders | World News

Novavax Inc's manufacturing capacity is sufficient to meet the U.S. demand for COVID-19 vaccines in 2021, which it believes could be as high as 500 million to 600 million doses, company executives said on Monday.&nbsp;

Novavax said last week its experimental vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early stage clinical trial.&nbsp;

Also read:&nbsp;<a href="/india-news/serum-institute-to-get-150-million-from-gates-foundation-for-covid-19-vaccine-318947" hreflang="en">Serum Institute to get $150 million from Gates Foundation for COVID-19 vaccine</a>

Novavax expects to begin producing vaccine at large scale in the beginning of 2021 and to be able to make "well over" 2 billion doses of its vaccine annually overall if its vaccine is authorized for use by regulators, the executives added during an investor call.

Novavax is still waiting on the U.S. Food and Drug Administration to review data from its early stage study of its vaccine candidate, but has said it expects to start a large Phase III trial as soon as late September.

Novavax research chief Gregory Glenn told Reuters last week the late-stage clinical trial could potentially glean enough data to obtain regulatory approvals as early as December.

Maryland-based Novavax has said its vaccine candidate, NVX-CoV2373, produced higher levels of the antibodies in healthy volunteers after two doses than those found in recovered COVID-19 patients and the vaccine was “well tolerated” overall.

Also read:&nbsp;<a href="/world/russia-to-register-worlds-first-covid-19-vaccine-next-week-318832" hreflang="en">Russia to register world's first COVID-19 vaccine next week</a>

"We are seeing a safety profile that in many ways looks like the safety profile of many other vaccines, so it's not going to prevent the use of the vaccine," Novavax's chief financial officer John Trizzino said in an interview.&nbsp;

The Novavax vaccine has received U.S. funding under Operation Warp Speed, the White House program to accelerate access to vaccines and treatments that can fight the virus.

The U.S. government in July agreed to pay Novavax $1.6 billion to help cover costs related to testing and manufacturing its vaccine, with the aim of procuring 100 million doses by January 2021.

Novavax Inc's manufacturing capacity is sufficient to meet the U.S. demand for COVID-19 vaccines in 2021, which it believes could be as high as 500 million to 600 million doses, company executives said on Monday.

Novavax Inc's manufacturing capacity is sufficient to meet the U.S. demand for COVID-19 vaccines in 2021, which it believes could be as high as 500 million to 600 million doses, company executives said on Monday. Novavax said last week its experimental vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early stage clinical trial. Also read: Serum Institute to get $150 million from Gates Foundation for COVID-19 vaccine Novavax expects to begin producing vaccine at large scale in the beginning of 2021 and to be able to make "well over" 2 billion doses of its vaccine annually overall if its vaccine is authorized for use by regulators, the executives added during an investor call. Novavax is still waiting on the U.S. Food and Drug Administration to review data from its early stage study of its vaccine candidate, but has said it expects to start a large Phase III trial as soon as late September. Novavax research chief Gregory Glenn told Reuters last week the late-stage clinical trial could potentially glean enough data to obtain regulatory approvals as early as December. Maryland-based Novavax has said its vaccine candidate, NVX-CoV2373, produced higher levels of the antibodies in healthy volunteers after two doses than those found in recovered COVID-19 patients and the vaccine was “well tolerated” overall. Also read: Russia to register world's first COVID-19 vaccine next week "We are seeing a safety profile that in many ways looks like the safety profile of many other vaccines, so it's not going to prevent the use of the vaccine," Novavax's chief financial officer John Trizzino said in an interview. The Novavax vaccine has received U.S. funding under Operation Warp Speed, the White House program to accelerate access to vaccines and treatments that can fight the virus. The U.S. government in July agreed to pay Novavax $1.6 billion to help cover costs related to testing and manufacturing its vaccine, with the aim of procuring 100 million doses by January 2021.

Novavax expects it can meet US COVID-19 vaccine demand in 2021, executives say

The global race for coronavirus vaccine could lead to generations Sputnik moment. The winning nation could get a jump start on protecting its citizens and restarting their economy. Watch DW-WION partnership report.

The global race to secure COVID-19 vaccine | DW-WION partnership

India's Health Minister Dr. Harsh Vardhan keynote address on India's COVID-19 strategy. He said that India is the biggest manufacturer of vaccines in terms of volume. It is therefore certain that India will be a production hub for COVID-19 vaccines.

WION Health Summit |  Dr. Harsh Vardhan's keynote address on India's COVID-19 strategy

Scientists around the world are racing to develop a vaccine to fight the Wuhan virus. In this report, WION's Palki Sharma takes you to the frontlines of the action - inside the laboratories that are making and testing the vaccine candidates.

Gravitas: Race for a vaccine, WION takes you to the frontlines

When will we get a vaccine? Who are the frontrunners? Who will get the vaccine first? How much will it cost? Is big pharma chasing profits? WION's Palki Sharma brings you the most definitive account of the global hunt for a vaccine.

Gravitas: When will we have a vaccine for Wuhan Virus? All your questions answered

Is the developed world locking up Wuhan Virus vaccine supplies - even before the scientists come up with one? WION's Palki Sharma tells you how leading countries have already ordered millions of doses in advance.

Gravitas: Vaccine for Wuhan Virus, Will the developed world lock up supplies?

US President Donald Trump vowed to defeat the coronavirus by "unleashing American scientific genius" as he toured a COVID-19 vaccine facility in the swing state of North Carolina on Monday. 
 
<a href="https://www.wionews.com/world/trumps-nsa-robert-obrien-tests-positive-for-coronavirus-316315">ALSO READ | Trump's NSA Robert O'Brien tests positive for coronavirus</a>

Trump appears to have pinned his hopes on the swift emergence of a successful vaccine to both contain the country's still raging epidemic and revive his faltering re-election hopes.

"We will achieve a victory over the virus by unleashing American scientific genius," he told reporters at Fujifilm Diosynth Biotechnologies in Morrisville, hours after it was revealed national security advisor Robert O'Brien had tested positive.

The facility has been awarded a contract to mass produce an experimental vaccine developed by Novavax, as part of a multi-billion dollar government initiative dubbed Operation Warp Speed.

The plan involves investing heavily in leading pharmaceuticals to aid their development and manufacturing efforts, with the goal of delivering 300 million doses of vaccine by January 2021.

It's "never been done before, but we suspect it's going to work, and work very well," added Trump, who later donned a black mask and toured the lab.

The United States is by far the worst-hit country in the world, with more than 4.2 million confirmed COVID-19 cases and nearly 150,000 deaths.

Though the number of new cases has leveled off over the past few days, the US has failed to push its curve down as other nations have done through lockdowns and physical distancing.

Trump's latest comments confirmed that the administration believes that, in America's case, only a vaccine can help.

"It's not masks. It's not shutting down the economy. Hopefully, it is American ingenuity that will allow for therapies and vaccines to ultimately conquer this," White House chief of staff Mark Meadows told ABC News on Sunday.

The virus has also repeatedly penetrated Trump's inner circle, with O'Brien the latest and most senior White House aide to test positive.

He "has been self-isolating and working from a secure location off site," the White House said in a statement Monday, adding that there was "no risk of exposure to the president or the vice president."

Others who have been previously infected include Vice President Mike Pence's spokeswoman Katie Miller, and Kimberly Guilfoyle, a top fundraiser for the Trump campaign and his elder son's girlfriend. 
Results by November?&nbsp;

The US has spent more than $6.3 billion since March to fund vaccine development efforts under Operation Warp Speed.

The program is unabashed in its aims to procure vaccines for the American people first -- unlike European leaders who have called for COVID-19 drugs to be a "global public good."

Pharmaceutical newcomer Moderna, which, alongside AstraZeneca and two Chinese firms is among those furthest in its development timeline, began the final stage of its clinical trial Monday.

The trial is being co-conducted by the National Institutes for Health (NIH) across the United States and is expected to enroll approximately 30,000 adult volunteers.

Participants will get two doses of the vaccine given 28 days apart.

The first volunteer, a Black woman identified as Robyn, participated in a video chat hosted by the NIH on Monday, telling viewers her friends and relatives had initially told her "it was a bad idea."

"And the reason for that was because in the African American community, we are all familiar with the Tuskegee experiments," she added, referring to a 40-year-study the US conducted on Black men to see the effects of untreated syphilis.

The men involved were kept in the dark about cures on purpose.

But, added Robyn, she was encouraged by laws that are now in place to prevent a repetition, and motivated by the desire to help others against a disease that disproportionately impacts communities of color.

An irony of the process is that, given the rampant nature of the US epidemic, results could come far sooner than the two years the trial is set to run.

Daily new cases have plateaued around the 66,000 mark for the past few days, making it more likely that trial participants will be exposed to the virus sooner rather than later.

"It's a really optimistic scenario. It could be November," Moderna CEO Stephane Bancel told CNBC on Monday.

US President Donald Trump vowed to defeat the coronavirus by "unleashing American scientific genius" as he toured a COVID-19 vaccine facility in the swing state of North Carolina on Monday.

US President Donald Trump vowed to defeat the coronavirus by "unleashing American scientific genius" as he toured a COVID-19 vaccine facility in the swing state of North Carolina on Monday. ALSO READ | Trump's NSA Robert O'Brien tests positive for coronavirus Trump appears to have pinned his hopes on the swift emergence of a successful vaccine to both contain the country's still raging epidemic and revive his faltering re-election hopes. "We will achieve a victory over the virus by unleashing American scientific genius," he told reporters at Fujifilm Diosynth Biotechnologies in Morrisville, hours after it was revealed national security advisor Robert O'Brien had tested positive. The facility has been awarded a contract to mass produce an experimental vaccine developed by Novavax, as part of a multi-billion dollar government initiative dubbed Operation Warp Speed. The plan involves investing heavily in leading pharmaceuticals to aid their development and manufacturing efforts, with the goal of delivering 300 million doses of vaccine by January 2021. It's "never been done before, but we suspect it's going to work, and work very well," added Trump, who later donned a black mask and toured the lab. The United States is by far the worst-hit country in the world, with more than 4.2 million confirmed COVID-19 cases and nearly 150,000 deaths. Though the number of new cases has leveled off over the past few days, the US has failed to push its curve down as other nations have done through lockdowns and physical distancing. Trump's latest comments confirmed that the administration believes that, in America's case, only a vaccine can help. "It's not masks. It's not shutting down the economy. Hopefully, it is American ingenuity that will allow for therapies and vaccines to ultimately conquer this," White House chief of staff Mark Meadows told ABC News on Sunday. The virus has also repeatedly penetrated Trump's inner circle, with O'Brien the latest and most senior White House aide to test positive. He "has been self-isolating and working from a secure location off site," the White House said in a statement Monday, adding that there was "no risk of exposure to the president or the vice president." Others who have been previously infected include Vice President Mike Pence's spokeswoman Katie Miller, and Kimberly Guilfoyle, a top fundraiser for the Trump campaign and his elder son's girlfriend. Results by November? The US has spent more than $6.3 billion since March to fund vaccine development efforts under Operation Warp Speed. The program is unabashed in its aims to procure vaccines for the American people first -- unlike European leaders who have called for COVID-19 drugs to be a "global public good." Pharmaceutical newcomer Moderna, which, alongside AstraZeneca and two Chinese firms is among those furthest in its development timeline, began the final stage of its clinical trial Monday. The trial is being co-conducted by the National Institutes for Health (NIH) across the United States and is expected to enroll approximately 30,000 adult volunteers. Participants will get two doses of the vaccine given 28 days apart. The first volunteer, a Black woman identified as Robyn, participated in a video chat hosted by the NIH on Monday, telling viewers her friends and relatives had initially told her "it was a bad idea." "And the reason for that was because in the African American community, we are all familiar with the Tuskegee experiments," she added, referring to a 40-year-study the US conducted on Black men to see the effects of untreated syphilis. The men involved were kept in the dark about cures on purpose. But, added Robyn, she was encouraged by laws that are now in place to prevent a repetition, and motivated by the desire to help others against a disease that disproportionately impacts communities of color. An irony of the process is that, given the rampant nature of the US epidemic, results could come far sooner than the two years the trial is set to run. Daily new cases have plateaued around the 66,000 mark for the past few days, making it more likely that trial participants will be exposed to the virus sooner rather than later. "It's a really optimistic scenario. It could be November," Moderna CEO Stephane Bancel told CNBC on Monday.

We will achieve a victory over the virus by unleashing America's scientific genius: Trump

July 23 was India's deadliest day of the outbreak of the coronavirus. The country has now more than 12 lakh confirmed cases with almost 30,000 deaths. Watch report.

COVID-19 pandemic: India records highest single-day surge

The researchers said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55.

COVID-19 Oxford vaccine phase 1 & 2 trails successful: Trails were conducted on 1077 people

The emergencies chief of WHO Michael Ryan has said that the two studies that offered new hope of a potential vaccine for the novel coronavirus on Monday are a 'positive result' but warns 'there is a long way to go'. 
 
<a href="https://www.wionews.com/world/oxford-astrazeneca-coronavirus-vaccine-trial-safe-produced-immune-response-data-reveals-314716">Also Read:&nbsp;Oxford-AstraZeneca coronavirus vaccine trial: Safe &amp; produced immune response, data reveals</a>

“We now need to move into larger-scale real-world trials. But it is good to see more data and more products moving into this very important phase of vaccine discovery,” Dr Michael Ryan said.

Ryan's comments came as scientists at Oxford University, in a paper published in The Lancet, said their experimental vaccine had been shown to trigger a protective immune response in hundreds of people who got the shot.

<a href="https://www.wionews.com/world/oxford-university-set-to-present-initial-trial-data-as-uk-secures-90-million-doses-of-potential-cornavirus-vaccines-314690">Also Read: UK secures 90 million doses of potential cornavirus vaccines</a>

According to reports, the vaccine developed by Oxford University and AstraZeneca in the UK showed it was "safe, well tolerated and immunogenic", the vaccine according to Lancet also showed single dose elicited both "humoral and cellular responses against the virus". 
&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-inside-the-russian-lab-that-is-making-the-covid-19-vaccine-314765/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

AstraZeneca's experimental coronavirus vaccine was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data revealed.

Vaccine developer Sarah Gilbert said: "There is still much work to be done before we can confirm if our vaccine will help manage the COVID-19 pandemic, but these early results hold promise," while adding, “we still do not know how strong an immune response we need to provoke to effectively protect against SARS-CoV-2 infection."

The Lancet medical journal said the vaccine AZD1222 under development by AstraZeneca and scientists at Britain's Oxford University did not prompt any serious side effects and elicited antibody and T-cell immune responses

The research took groups with co-morbidities, health-care workers and those with a higher risk for efficacy, safety and immunogenicity towards the virus given as single dose or two-dose administration regimen in further trials conducted in the UK and overseas.

Phase-3 trials are now underway in Brazil, South Africa and the UK. According to reports, no serious adverse reactions to the virus occurred. The majority of adverse events reported were mild or moderate in severity.

(With inputs from agencies)

The emergencies chief of WHO Michael Ryan has said that the two studies that offered new hope of a potential vaccine for the novel coronavirus on Monday are a 'positive result' but warns 'there is a long way to go'.

The emergencies chief of WHO Michael Ryan has said that the two studies that offered new hope of a potential vaccine for the novel coronavirus on Monday are a 'positive result' but warns 'there is a long way to go'. Also Read: Oxford-AstraZeneca coronavirus vaccine trial: Safe & produced immune response, data reveals “We now need to move into larger-scale real-world trials. But it is good to see more data and more products moving into this very important phase of vaccine discovery,” Dr Michael Ryan said. Ryan's comments came as scientists at Oxford University, in a paper published in The Lancet, said their experimental vaccine had been shown to trigger a protective immune response in hundreds of people who got the shot. Also Read: UK secures 90 million doses of potential cornavirus vaccines According to reports, the vaccine developed by Oxford University and AstraZeneca in the UK showed it was "safe, well tolerated and immunogenic", the vaccine according to Lancet also showed single dose elicited both "humoral and cellular responses against the virus". AstraZeneca's experimental coronavirus vaccine was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data revealed. Vaccine developer Sarah Gilbert said: "There is still much work to be done before we can confirm if our vaccine will help manage the COVID-19 pandemic, but these early results hold promise," while adding, “we still do not know how strong an immune response we need to provoke to effectively protect against SARS-CoV-2 infection." The Lancet medical journal said the vaccine AZD1222 under development by AstraZeneca and scientists at Britain's Oxford University did not prompt any serious side effects and elicited antibody and T-cell immune responses The research took groups with co-morbidities, health-care workers and those with a higher risk for efficacy, safety and immunogenicity towards the virus given as single dose or two-dose administration regimen in further trials conducted in the UK and overseas. Phase-3 trials are now underway in Brazil, South Africa and the UK. According to reports, no serious adverse reactions to the virus occurred. The majority of adverse events reported were mild or moderate in severity. (With inputs from agencies)

COVID-19 vaccine: WHO applauds Oxford coronavirus vaccine data, but warns there’s still a long way to go

The coronavirus pandemic continues to escalate in the US. The country recorded more than 68,400 cases in the last 24-hours alone. Watch report.

Coronavirus Pandemic: Massive surge in COVID-19 cases in South and West of US

Moscow’s Sechenov University has completed tests on volunteers of the world’s first vaccine against COVID-19. The Russian embassy in India tweeted. “Sechenov University has successfully completed tests on volunteers of the world’s first vaccine against #COVID19. The #vaccine is safe. The volunteers will be discharged on July 15 and July 20,” chief researcher Elena Smolyarchuk told TASS".

Russia's Sechenov University claims making vaccine against COVID-19

AstraZeneca is one of the front runners in the race to protect against coronavirus for about a year, the company's chief executive told a Belgian radio station on Tuesday.

AstraZeneca is one of the front runners in the race to protect against coronavirus for about a year, the company's chief executive told a Belgian radio station on Tuesday. Also read: COVID-19: Beijing reports another 27 cases amid second wave fears The vaccines developed by the University of Oxford have begun with human trials with a phase I trial in Britain due to end soon and a phase III trial already begun, Pascal Soriot told broadcaster Bel RTL. "We think that it will protect for about a year," Soriot said. The British drugmaker has signed contracts with France, Germany, Italy and the Netherlands to supply the EU with up to 400 million doses of the vaccine. Britain and the United States are also a part of the deal. "If all goes well, we will have the results of the clinical trials in August/September. We are manufacturing in parallel. We will be ready to deliver from October if all goes well," Soriot said. (Inputs from Reuters)

Vaccine developed by AstraZeneca most likely to protect for a year: CEO

At a time when countries across the globe are pushing their efforts to find a vaccine to treat novel coronavirus, an institute in US is experimenting with the saliva of mosquitoes to build a vaccine that can help in protecting against all the pathogens that insects transmit into humans.&nbsp;

The study led by Jessica Manning and conducted by US National Institute of Allergy and Infectious Diseases focuses on saliva protein of mosquitoes to build a universal vaccine that can resist malaria, dengue, chikungunya, Zika, West Nile, Mayaro viruses, yellow fever, and any other related disease that may emerge.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/covid-19-global-vaccine-mission-secures-74-billion-india-joins-uks-mission-303478">COVID 19: Global vaccine mission secures $7.4 billion; India joins UK's mission</a>

The Lancet, on Thursday, published the results of the first-ever clinical trial of a mosquito spit study in humans.

Also read |&nbsp;<a href="https://www.wionews.com/world/race-for-covid-19-vaccine-china-wants-to-act-god-in-a-world-deep-in-pain-304359">Race for Covid-19 vaccine: China wants to act god in a world deep in pain</a>

It said that the vaccine was safe and activated antibody and cellular responses.

In the phase 1 trial of the vaccine, 49 health people were chosen and were randomly assigned to receive one of two versions of the vaccine or a placebo.&nbsp;

After a few weeks, mosquitoes were placed on the arms of the participants where their immune response to the mosquito saliva protein was seen.&nbsp;

However, pathogens were not involved in this trial.&nbsp;

According to the World Health Organization (WHO), Malaria alone is responsible for deaths of over 400,000 people each year.&nbsp;

Underdeveloped and developing nations generally contribute to deaths from&nbsp;this disease.

The coronavirus outbreak has brought focus on the research and vaccines of infectious disease, and one of the main concerns are pathogens spread by mosquitoes.&nbsp;

At a time when countries across the globe are pushing their efforts to find a vaccine to treat novel coronavirus, an institute in US is experimenting with the saliva of mosquitoes to build a vaccine that can help in protecting against all the pathogens that insects transmit into humans.

At a time when countries across the globe are pushing their efforts to find a vaccine to treat novel coronavirus, an institute in US is experimenting with the saliva of mosquitoes to build a vaccine that can help in protecting against all the pathogens that insects transmit into humans. The study led by Jessica Manning and conducted by US National Institute of Allergy and Infectious Diseases focuses on saliva protein of mosquitoes to build a universal vaccine that can resist malaria, dengue, chikungunya, Zika, West Nile, Mayaro viruses, yellow fever, and any other related disease that may emerge. Also read | COVID 19: Global vaccine mission secures $7.4 billion; India joins UK's mission The Lancet, on Thursday, published the results of the first-ever clinical trial of a mosquito spit study in humans. Also read | Race for Covid-19 vaccine: China wants to act god in a world deep in pain It said that the vaccine was safe and activated antibody and cellular responses. In the phase 1 trial of the vaccine, 49 health people were chosen and were randomly assigned to receive one of two versions of the vaccine or a placebo. After a few weeks, mosquitoes were placed on the arms of the participants where their immune response to the mosquito saliva protein was seen. However, pathogens were not involved in this trial. According to the World Health Organization (WHO), Malaria alone is responsible for deaths of over 400,000 people each year. Underdeveloped and developing nations generally contribute to deaths from this disease. The coronavirus outbreak has brought focus on the research and vaccines of infectious disease, and one of the main concerns are pathogens spread by mosquitoes.

US institute develops vaccine from mosquito spit that could prevent next epidemic

European Union countries -- France, Italy and Belgium -- have expressed their displeasure about using hydroxychloroquine for COVID-19 treatment.&nbsp;

Paris, on Wednesday, revoked a decree allowing doctors to use the drug for severely ill coronavirus patients. The Italian and Belgian officials have asked the concerned authorities to suspend the usage of the drug, except in clinical trials.

<a href="https://www.wionews.com/world/after-trump-el-salvadors-president-says-he-is-taking-hydroxychloroquine-301318">Also read: After Trump, El Salvador's President says he is taking hydroxychloroquine</a>

The drug, which is being used as a treatment for critically ill coro navirus patients, is believed to have safety concerns. However, US President Donald Trump and Brazil's President Jair Bolsonaro, have promoted the usage of the drug.

These countries are not the first ones to object against the usage of this drug. World Health Orhanization (WHO), few days ago, suspended a global trial of hydroxychloroquine, citing safety concerns. Oxford University, too, followed the suit and paused a global trial within a week of starting it.

WHO chief Tedros Adhanom Ghebreyesus earlier said that "hydroxychloroquine and chloroquine are accepted as generally safe for use in patients with autoimmune diseases or malaria."

A research by France’s Pasteur Institute suggested 98% of people with mild coronavirus developed antibodies capable of neutralising the virus a month later, raising hopes that everyone who has had the disease may enjoy some immunity.

Donald Trump and Salvadoran President Nayib Bukele have both publically announced that they have been taking hydroxychloroquine. Both the Presidents have bene heavily criticized and trolled for this admission.

An observational study published in the Lancet of nearly 100,000 patients in 671 hospitals has suggested hydroxychloroquine – promoted by the controversial French infectious diseases specialist Didier Raoult – might increase mortality rates.

(With inputs from Reuters)

European Union countries -- France, Italy and Belgium -- have expressed their displeasure about using hydroxychloroquine for COVID-19 treatment. Paris, on Wednesday, revoked a decree allowing doctors to use the drug for severely ill coronavirus patients.

European Union countries -- France, Italy and Belgium -- have expressed their displeasure about using hydroxychloroquine for COVID-19 treatment. Paris, on Wednesday, revoked a decree allowing doctors to use the drug for severely ill coronavirus patients. The Italian and Belgian officials have asked the concerned authorities to suspend the usage of the drug, except in clinical trials. Also read: After Trump, El Salvador's President says he is taking hydroxychloroquine The drug, which is being used as a treatment for critically ill coro navirus patients, is believed to have safety concerns. However, US President Donald Trump and Brazil's President Jair Bolsonaro, have promoted the usage of the drug. These countries are not the first ones to object against the usage of this drug. World Health Orhanization (WHO), few days ago, suspended a global trial of hydroxychloroquine, citing safety concerns. Oxford University, too, followed the suit and paused a global trial within a week of starting it. WHO chief Tedros Adhanom Ghebreyesus earlier said that "hydroxychloroquine and chloroquine are accepted as generally safe for use in patients with autoimmune diseases or malaria." A research by France’s Pasteur Institute suggested 98% of people with mild coronavirus developed antibodies capable of neutralising the virus a month later, raising hopes that everyone who has had the disease may enjoy some immunity. Donald Trump and Salvadoran President Nayib Bukele have both publically announced that they have been taking hydroxychloroquine. Both the Presidents have bene heavily criticized and trolled for this admission. An observational study published in the Lancet of nearly 100,000 patients in 671 hospitals has suggested hydroxychloroquine – promoted by the controversial French infectious diseases specialist Didier Raoult – might increase mortality rates. (With inputs from Reuters)

COVID 19: France, Italy and Belgium ban usage of hydroxychloroquine

Anti-vaxxers are protesting in Europe and the United States. The prospect of compulsory vaccination has boosted a protest movement across cities in Europe. Watch report.

Bill Gates slammed by anti-vaxxers for funding research

As the number of positive cases is rising on a daily basis in the world, the pressure on scientists&nbsp;is increasing to develop a cure for coronavirus.

Few weeks ago, the European Union (EU) had chaired a global online summit for coronavirus research and had managed to secure pledges of $8bn (£6.5bn) from almost 40 countries and donors. However, the US and Russia did not participate in the summit.

Following that, Sanofi, a&nbsp;US Biomedical Advanced Research and Development Authority (BARDA) funded company, claimed that the US had&nbsp;"the right to the largest pre-order because it's invested in taking the risk". Thi statement by Sanofi's CEO Paul Hudson attracted a lot of criticism.

<a href="https://www.wionews.com/world/global-coronavirus-death-toll-rises-to-more-than-300000-298758">Also read:&nbsp;Global coronavirus death toll rises to more than 300,000</a>

Although, Sanofi is partly funded by US' BARDA, it has received&nbsp;tens of millions of euros in tax credits from the French government to help its research, in the recent years.

Paul's statement was immediately rebuked by the French Prime Minister Edouard Philippe who claimed that access to the vaccine for all was non-negotiable.

On Friday,&nbsp;Sanofi's Chairman came to Paul's rescue and claimed that the CEO's words were distorted and misinterpreted. He also promised equal access for everyone.

"I am going to be extremely clear: there will be no particular advance for any country," Serge Weinberg told a local media organization.

French&nbsp;Prime Minister Philippe and President&nbsp;Emmanuel Macron, too, assured that the vaccine, when developed, will be accessible for all equally.

"The vaccine against Covid-19 should be a global public good and its access needs to be equitable and universal," European Commission spokesman Stefan de Keersmaecker told a media organization.

As the number of positive cases is rising on a daily basis in the world, the pressure on scientists is increasing to develop a cure for coronavirus. Few weeks ago, the European Union (EU) had chaired a global online summit for coronavirus research and had managed to secure pledges of $8bn (£6.

As the number of positive cases is rising on a daily basis in the world, the pressure on scientists is increasing to develop a cure for coronavirus. Few weeks ago, the European Union (EU) had chaired a global online summit for coronavirus research and had managed to secure pledges of $8bn (£6.5bn) from almost 40 countries and donors. However, the US and Russia did not participate in the summit. Following that, Sanofi, a US Biomedical Advanced Research and Development Authority (BARDA) funded company, claimed that the US had "the right to the largest pre-order because it's invested in taking the risk". Thi statement by Sanofi's CEO Paul Hudson attracted a lot of criticism. Also read: Global coronavirus death toll rises to more than 300,000 Although, Sanofi is partly funded by US' BARDA, it has received tens of millions of euros in tax credits from the French government to help its research, in the recent years. Paul's statement was immediately rebuked by the French Prime Minister Edouard Philippe who claimed that access to the vaccine for all was non-negotiable. On Friday, Sanofi's Chairman came to Paul's rescue and claimed that the CEO's words were distorted and misinterpreted. He also promised equal access for everyone. "I am going to be extremely clear: there will be no particular advance for any country," Serge Weinberg told a local media organization. French Prime Minister Philippe and President Emmanuel Macron, too, assured that the vaccine, when developed, will be accessible for all equally. "The vaccine against Covid-19 should be a global public good and its access needs to be equitable and universal," European Commission spokesman Stefan de Keersmaecker told a media organization.

There will be no advance for any country: says Sanofi's Chairman for COVID-19 vaccine

14 year old boy from London died after suffering from a Kawasaki like disease linked to the coronavirus.

COVID 19: Rare Covid-linked syndrome impacting children, 14 year old boy died

The Indian Council of Medical Research (ICMR) has announced a partnership with Bharat Biotech International Limited (BBIL) on Saturday&nbsp;to develop a vaccine for coronavirus.

The vaccine will be developed using the virus strain isolated at the National Institute of Virology (NIV), Pune.

<a href="https://www.wionews.com/india-news/total-covid-19-cases-in-india-cross-56000-mark-16539-patients-cured-297349">Also read:&nbsp;Total COVID-19 cases in India cross 56,000-mark; 16539 patients cured</a>

The two bodies have started the work on developing the vaccine, with ICMR-NIV providing support to BBIL.

"The strain has been successfully transferred from NIV to Bharat Biotech International Ltd. (BBIL). Work on vaccine development has been initiated between the two partners. ICMR-NIV will provide continuous support to BBIL for vaccine development. ICMR and BBIL will seek fast-track approval to expedite vaccine development, subsequent animal studies and clinical evaluation of the candidate vaccine," stated the press release.

Dr Y K Gupta is chairing the committee for Evaluation of Research Proposals at ICMR. Earlier today he claimed that the data available to to the officials is not enough to perform clinical study on using Ganga water for treatment of coronavirus.

(With inputs from ANI)

The Indian Council of Medical Research (ICMR) has announced a partnership with Bharat Biotech International Limited (BBIL) on Saturday to develop a vaccine for coronavirus.

The Indian Council of Medical Research (ICMR) has announced a partnership with Bharat Biotech International Limited (BBIL) on Saturday to develop a vaccine for coronavirus. The vaccine will be developed using the virus strain isolated at the National Institute of Virology (NIV), Pune. Also read: Total COVID-19 cases in India cross 56,000-mark; 16539 patients cured The two bodies have started the work on developing the vaccine, with ICMR-NIV providing support to BBIL. "The strain has been successfully transferred from NIV to Bharat Biotech International Ltd. (BBIL). Work on vaccine development has been initiated between the two partners. ICMR-NIV will provide continuous support to BBIL for vaccine development. ICMR and BBIL will seek fast-track approval to expedite vaccine development, subsequent animal studies and clinical evaluation of the candidate vaccine," stated the press release. Dr Y K Gupta is chairing the committee for Evaluation of Research Proposals at ICMR. Earlier today he claimed that the data available to to the officials is not enough to perform clinical study on using Ganga water for treatment of coronavirus. (With inputs from ANI)

ICMR partners with BBIL to develop indigenous COVID-19 vaccine

Pope Francis called on Sunday for international scientific cooperation to discover a vaccine for the coronavirus and said any successful vaccine should be made available around the world.

Francis, who has been delivering his Sunday address from the papal library instead of St. Peter’s Square because of the lockdown in Italy, thanked all those around the world who were providing essential services.

<a href="https://www.wionews.com/world/kim-jong-un-did-not-go-through-any-surgery-south-korean-official-claims-296418">Also read:&nbsp;Kim Jong Un did not go through any surgery: South Korean official claims</a>

He encouraged international cooperation to deal with the crisis and combat the virus, which has infected nearly 3.5 million people and killed more than 240,000 people worldwide.

“In fact, it is important to unite scientific capabilities, in a transparent and impartial way to find vaccines and treatments,” he said.

Francis said it was also important to “guarantee universal access to essential technologies that allow each infected person, in every part of the world, to receive the necessary medical treatment.”

<a href="https://www.wionews.com/world/spain-enjoys-the-new-found-freedom-post-lockdown-296409">Also read:&nbsp;Spain enjoys the new-found freedom post-lockdown</a>

World leaders pledged in April to accelerate work on tests, drugs and vaccines against COVID-19 and to share them around the globe, but the United States did not take part in the launch of the World Health Organization (WHO) initiative.

U.S. President Donald Trump has said the WHO was slow to react to the outbreak and was being “China-centric”, and as a consequence has announced a suspension of funding. The WHO has defended its handling of the crisis.

A number of pharmaceutical companies around the world have developed tests to identify antibodies that develop after somebody has come into contact with the virus.

The Trump administration is planning to speed up development of a coronavirus vaccine with the goal of having 100 million doses ready by the end of 2020, according to a senior U.S. administration official.

Most experts have suggested clinical trials to guarantee a vaccine is safe and effective could take a minimum of 12 to 18 months.

On Sunday, the pope also backed a proposal by an inter-religious group known as the Higher Committee on Human Fraternity for an international day of prayer and fasting on May 14 to ask God to help humanity overcome the pandemic.

Pope Francis called on Sunday for international scientific cooperation to discover a vaccine for the coronavirus and said any successful vaccine should be made available around the world.

Pope Francis called on Sunday for international scientific cooperation to discover a vaccine for the coronavirus and said any successful vaccine should be made available around the world. Francis, who has been delivering his Sunday address from the papal library instead of St. Peter’s Square because of the lockdown in Italy, thanked all those around the world who were providing essential services. Also read: Kim Jong Un did not go through any surgery: South Korean official claims He encouraged international cooperation to deal with the crisis and combat the virus, which has infected nearly 3.5 million people and killed more than 240,000 people worldwide. “In fact, it is important to unite scientific capabilities, in a transparent and impartial way to find vaccines and treatments,” he said. Francis said it was also important to “guarantee universal access to essential technologies that allow each infected person, in every part of the world, to receive the necessary medical treatment.” Also read: Spain enjoys the new-found freedom post-lockdown World leaders pledged in April to accelerate work on tests, drugs and vaccines against COVID-19 and to share them around the globe, but the United States did not take part in the launch of the World Health Organization (WHO) initiative. U.S. President Donald Trump has said the WHO was slow to react to the outbreak and was being “China-centric”, and as a consequence has announced a suspension of funding. The WHO has defended its handling of the crisis. A number of pharmaceutical companies around the world have developed tests to identify antibodies that develop after somebody has come into contact with the virus. The Trump administration is planning to speed up development of a coronavirus vaccine with the goal of having 100 million doses ready by the end of 2020, according to a senior U.S. administration official. Most experts have suggested clinical trials to guarantee a vaccine is safe and effective could take a minimum of 12 to 18 months. On Sunday, the pope also backed a proposal by an inter-religious group known as the Higher Committee on Human Fraternity for an international day of prayer and fasting on May 14 to ask God to help humanity overcome the pandemic.

Pope says coronavirus vaccine must be shared worldwide

While scientists all around the world are racing to develop the vaccine soon for COVID-19, Oxford University scientists have claimed that the coronavirus vaccine could be available by September this year. Watch report.

Why the Oxford group is ahead in developing the COVID-19 vaccine?

The United Nations children’s agency Unicef said hundreds of thousands were at risk as lockdowns across South Asia halted immunisation drives and parents refrained from taking their children to doctors to be inoculated.

“While the Covid-19 virus does not appear to make many children seriously ill, the health of hundreds of thousands of children could be impacted by this disruption of regular immunisation services,” said Jean Gough, director of Unicef’s South Asia office.

<a href="https://www.wionews.com/world/us-considering-coronavirus-checks-on-international-flights-trump-295404">Also read:&nbsp;US considering coronavirus checks on international flights: Trump</a>

“This is a very serious threat. Early action is key.” Bangladesh and Nepal have halted their measles and rubella campaigns while Pakistan and Afghanistan have suspended their polio drives since the Covid-19 pandemic.

Unicef noted that “sporadic” outbreaks of preventable diseases that can be cured with vaccines, including the measles and diphtheria, have emerged in Bangladesh, Pakistan and Nepal.

Vaccine stocks were also running low in some countries in the region thanks to lockdowns and travel bans which have disrupted supply chains.

<a href="https://www.wionews.com/india-news/covid-19-outbreak-is-mumbai-turning-into-indias-new-york-city-295323">Also read:&nbsp;COVID-19 outbreak: Is Mumbai turning into India's New York City?</a>

“Unicef strongly recommends that, where immunisation campaigns are suspended, governments begin rigorous planning now to intensify immunisation activities once the Covid-19 pandemic is under control,” the agency said in a statement.

It added that as long as health workers take hygiene precautions, there was no reason for vaccinations not to continue.

The agency estimated that 4.5 million of South Asia’s children had already missed out on routine immunisations, even before the coronavirus pandemic struck.

The United Nations children’s agency Unicef said hundreds of thousands were at risk as lockdowns across South Asia halted immunisation drives and parents refrained from taking their children to doctors to be inoculated.

The United Nations children’s agency Unicef said hundreds of thousands were at risk as lockdowns across South Asia halted immunisation drives and parents refrained from taking their children to doctors to be inoculated. “While the Covid-19 virus does not appear to make many children seriously ill, the health of hundreds of thousands of children could be impacted by this disruption of regular immunisation services,” said Jean Gough, director of Unicef’s South Asia office. Also read: US considering coronavirus checks on international flights: Trump “This is a very serious threat. Early action is key.” Bangladesh and Nepal have halted their measles and rubella campaigns while Pakistan and Afghanistan have suspended their polio drives since the Covid-19 pandemic. Unicef noted that “sporadic” outbreaks of preventable diseases that can be cured with vaccines, including the measles and diphtheria, have emerged in Bangladesh, Pakistan and Nepal. Vaccine stocks were also running low in some countries in the region thanks to lockdowns and travel bans which have disrupted supply chains. Also read: COVID-19 outbreak: Is Mumbai turning into India's New York City? “Unicef strongly recommends that, where immunisation campaigns are suspended, governments begin rigorous planning now to intensify immunisation activities once the Covid-19 pandemic is under control,” the agency said in a statement. It added that as long as health workers take hygiene precautions, there was no reason for vaccinations not to continue. The agency estimated that 4.5 million of South Asia’s children had already missed out on routine immunisations, even before the coronavirus pandemic struck.

South Asia may face new health crisis as children miss vaccinations: UN

Oxford university has started human trials for a potential COVID-19 vaccine. Two volunteers have been injected as part of the trial out of a group of 800.

They will be monitored for 48 hours. Scientists will then gradually start injecting more volunteers.&nbsp;

The team started research on a COVID-19 vaccine in February and hopes to have a vaccine ready by September.

Hundreds of Hong Kong students appeared for their final secondary school exams on Friday.

The students were asked to arrive early to have their temperatures checked and their desks were placed about 6 feet apart.

The number of cases in the city has come down. &nbsp;But social distancing measures remain in place.

On Monday, the city reported no new cases for the first time since early March.

Russia is all set to open a temporary hospital in St Petersburg for coronavirus patients by the end of the week.

The facility will have over 1,000 beds.

The Defence Ministry is building 16 brand new hospitals across the country which are expected to be ready by mid-May.

Wearing masks is now mandatory in Brazil's Rio de Janeiro to curb the spread of COVID-19.

To encourage people to follow the rule, the state authorities decorated about 40 statues with masks. Brazil has recorded over 49,000 confirmed cases.

On Thursday, demonstrators in Washington DC &nbsp;placed fake body bags outside the trump hotel. Expressing their anger against the mounting coronavirus death toll.&nbsp;

Chanting slogans like "Trump lies, people die!", the protesters called for trump's resignation over his handling of the crisis.

The United State's tally is now nearing 900,000 cases, and nearly 50,000 people have been killed by the virus.

Separated by a transparent plastic barrier, residents of a French nursing home reunited with their family members for the first time since the coronavirus outbreak.

The French government has relaxed restrictions on visits to retirement homes. 8,309 people have died from coronavirus-related illnesses in French nursing homes --- accounting for 60% of France's total death toll.

An auto-rickshaw resembling the coronavirus is on a mission in southern India.

Through loudspeaker announcements, it is spreading awareness in Chennai city on how littering and spitting contribute to the spread of the virus.

Street artist Banksy's famous mural &nbsp;"girl with a pierced eardrum" now has a COVID-19 facelift.

The mural now wears a blue surgical face mask. The mural was painted on a building in the artist's home city of Bristol in England in 2014. Whether the addition has been made by the artist is not known.

Oxford university has started human trials for a potential COVID-19 vaccine. Two volunteers have been injected as part of the trial out of a group of 800. They will be monitored for 48 hours.

Oxford university has started human trials for a potential COVID-19 vaccine. Two volunteers have been injected as part of the trial out of a group of 800. They will be monitored for 48 hours. Scientists will then gradually start injecting more volunteers. The team started research on a COVID-19 vaccine in February and hopes to have a vaccine ready by September. Hundreds of Hong Kong students appeared for their final secondary school exams on Friday. The students were asked to arrive early to have their temperatures checked and their desks were placed about 6 feet apart. The number of cases in the city has come down. But social distancing measures remain in place. On Monday, the city reported no new cases for the first time since early March. Russia is all set to open a temporary hospital in St Petersburg for coronavirus patients by the end of the week. The facility will have over 1,000 beds. The Defence Ministry is building 16 brand new hospitals across the country which are expected to be ready by mid-May. Wearing masks is now mandatory in Brazil's Rio de Janeiro to curb the spread of COVID-19. To encourage people to follow the rule, the state authorities decorated about 40 statues with masks. Brazil has recorded over 49,000 confirmed cases. On Thursday, demonstrators in Washington DC placed fake body bags outside the trump hotel. Expressing their anger against the mounting coronavirus death toll. Chanting slogans like "Trump lies, people die!", the protesters called for trump's resignation over his handling of the crisis. The United State's tally is now nearing 900,000 cases, and nearly 50,000 people have been killed by the virus. Separated by a transparent plastic barrier, residents of a French nursing home reunited with their family members for the first time since the coronavirus outbreak. The French government has relaxed restrictions on visits to retirement homes. 8,309 people have died from coronavirus-related illnesses in French nursing homes --- accounting for 60% of France's total death toll. An auto-rickshaw resembling the coronavirus is on a mission in southern India. Through loudspeaker announcements, it is spreading awareness in Chennai city on how littering and spitting contribute to the spread of the virus. Street artist Banksy's famous mural "girl with a pierced eardrum" now has a COVID-19 facelift. The mural now wears a blue surgical face mask. The mural was painted on a building in the artist's home city of Bristol in England in 2014. Whether the addition has been made by the artist is not known.

Coronavirus tracker: From human trials at Oxford to painted murals at Bristol!

At the moment there is no singular cure to coronavirus, medical specialist can only treat symptoms. From potential vaccines to antibody treatment. Watch our report to know more.

Watch: The race to develop COVID-19 vaccine

According to the study, national differences in impact of coronavirus could be partially explained by the different national policies respect to a TB vaccine called Bacillus Calmette-Guerin (BCG) vaccine.

Study that projects TB vaccine can protect from COVID-19 is legit?

vaccine

Vaccine, News on Vaccine, stories on Vaccine, articles on Vaccine, Vaccine stories at Wion, Vaccine news, Vaccine latest news